1. REFACELL-IPF (Under Clinical Trial)
Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic pulmonary fibrosis (IPF) is a progressive, life threatening disease that is characterized by scarring of lung tissue and symptomatically by exertion dyspnoea of unknown cause, primarily occurring in older adults, limited to the lungs. Of the 150 recognized interstitial lung disease (ILD), IPF is the most common and one of the most deleterious
IPF patients generally have a poor prognosis, and, to date, no proven effective therapies are available for treatment other than lung transplantation. Median survival of patienmts is between 3 to 5 yrs. Adult stem cell therapy may prove to be a valuable therapeutic option for IPF. Given the current scenario with IPF and our findings, adult stem cell therapy may prove to be the most effective therapeutic option for IPF.

2. REFACELL-CLI (Under Clinical Trial)
Critical Limb Ischemia
Critical Limb Ischemia (CLI) defines a subset of patients with peripheral arterial occlusive disease that manifests with ischemic rest pain, ulcerations, or gangrene. Despite collateral vessel development and compensatory vasodilation in patients with CLI, arterial perfusion is severely compromised and is not sufficient to meet the metabolic needs of the extremity. As a result, not only are patients with CLI functionally disabled, but they are also at a high risk for limb loss and cardiovascular and cerebrovascular complications.
The prognosis for limb salvage as well as survival is frequently dismal in patients with chronic CLI. Within a 6-month period, 20% of patients die, 35% live but require amputation, and the remaining 45% live with no immediate need for amputation.

3. REFACELL-T1D (Clinical Trials Planned)
Type-1 Diabetes (T1D)
Diabetes with its acute and long-term complications, and the myriad of disorders associated with it, is a major health hazard.
6.5% of the total global population is living with T1D and this number is expected grow to 438 million by 2030 with predicted net losses in National Income of USD 336 billion in India.

4. REFACELL-DCM (Clinical Trials Planned)
Dilated Cardiomyopathy (DCM) is the most common type of non-ischemic cardiomyopathy. In dilated cardiomyopathy, the heart becomes weak and enlarged & its ability to pump blood is decreased. About 50% of patients diagnosed with DCM do not live for more than 5 years.
Conventional therapy for DCM is only able to stop disease progression but fails to do so in a majority of cases, leaving heart transplant as the only viable option for the patient. The shortage of donors, the problems of imcompatibility and the high procedural costs have made cardiac transplantation a limited therapeutic option. In this scenario, new therapies are needed and the use of stem cells to regenerate the diseased heart tissue is a promising option.